275 related articles for article (PubMed ID: 29100963)
1. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
2. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
[TBL] [Abstract][Full Text] [Related]
3. Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
Kojonazarov B; Sydykov A; Pullamsetti SS; Luitel H; Dahal BK; Kosanovic D; Tian X; Majewski M; Baumann C; Evans S; Phillips P; Fairman D; Davie N; Wayman C; Kilty I; Weissmann N; Grimminger F; Seeger W; Ghofrani HA; Schermuly RT
Int J Cardiol; 2013 Sep; 167(6):2630-7. PubMed ID: 22854298
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
5. Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension.
Conzatti A; Colombo R; Siqueira R; Campos-Carraro C; Turck P; Luz de Castro A; Belló-Klein A; Sander da Rosa Araujo A
J Cardiovasc Pharmacol; 2024 Jun; 83(6):612-620. PubMed ID: 38547510
[TBL] [Abstract][Full Text] [Related]
6. Role of Src tyrosine kinases in experimental pulmonary hypertension.
Pullamsetti SS; Berghausen EM; Dabral S; Tretyn A; Butrous E; Savai R; Butrous G; Dahal BK; Brandes RP; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Rosenkranz S; Schermuly RT
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1354-65. PubMed ID: 22516066
[TBL] [Abstract][Full Text] [Related]
7. Imatinib attenuates monocrotaline pulmonary hypertension and has potent vasodilator activity in pulmonary and systemic vascular beds in the rat.
Pankey EA; Thammasiboon S; Lasker GF; Baber S; Lasky JA; Kadowitz PJ
Am J Physiol Heart Circ Physiol; 2013 Nov; 305(9):H1288-96. PubMed ID: 23997103
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.
Kosanovic D; Kojonazarov B; Luitel H; Dahal BK; Sydykov A; Cornitescu T; Janssen W; Brandes RP; Davie N; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Schermuly RT
Respir Res; 2011 Jun; 12():87. PubMed ID: 21699729
[TBL] [Abstract][Full Text] [Related]
9. Impact of dietary iron restriction on the development of monocrotaline-induced pulmonary vascular remodeling and right ventricular failure in rats.
Naito Y; Hosokawa M; Hao H; Sawada H; Hirotani S; Iwasaku T; Okuhara Y; Eguchi A; Hirota S; Ohyanagi M; Tsujino T; Masuyama T
Biochem Biophys Res Commun; 2013 Jun; 436(2):145-51. PubMed ID: 23707944
[TBL] [Abstract][Full Text] [Related]
10. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Jasińska-Stroschein M; Owczarek J; Plichta P; Orszulak-Michalak D
Pharmacology; 2014; 93(3-4):145-50. PubMed ID: 24662671
[TBL] [Abstract][Full Text] [Related]
11. Propylthiouracil attenuates monocrotaline-induced pulmonary arterial hypertension in rats.
Sun CK; Yuen CM; Kao YH; Chang LT; Chua S; Sheu JJ; Yen CH; Ko SF; Yip HK
Circ J; 2009 Sep; 73(9):1722-30. PubMed ID: 19602776
[TBL] [Abstract][Full Text] [Related]
12. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.
Umar S; de Visser YP; Steendijk P; Schutte CI; Laghmani el H; Wagenaar GT; Bax WH; Mantikou E; Pijnappels DA; Atsma DE; Schalij MJ; van der Wall EE; van der Laarse A
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1606-16. PubMed ID: 19783775
[TBL] [Abstract][Full Text] [Related]
13. [Early treatment with hepatocyte growth factor improves pulmonary artery and right ventricular remodeling in rats with pulmonary artery hypertension by modulating cytokines expression].
Wang X; Wang Y; Rong S; Ma H
Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jun; 37(6):427-32. PubMed ID: 25200042
[TBL] [Abstract][Full Text] [Related]
14. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W
Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.
Paffett ML; Lucas SN; Campen MJ
Vascul Pharmacol; 2012; 56(1-2):64-73. PubMed ID: 22146233
[TBL] [Abstract][Full Text] [Related]
16. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
Bogaard HJ; Natarajan R; Mizuno S; Abbate A; Chang PJ; Chau VQ; Hoke NN; Kraskauskas D; Kasper M; Salloum FN; Voelkel NF
Am J Respir Crit Care Med; 2010 Sep; 182(5):652-60. PubMed ID: 20508210
[TBL] [Abstract][Full Text] [Related]
17. Direct and indirect protection of right ventricular function by estrogen in an experimental model of pulmonary arterial hypertension.
Liu A; Schreier D; Tian L; Eickhoff JC; Wang Z; Hacker TA; Chesler NC
Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H273-83. PubMed ID: 24906919
[TBL] [Abstract][Full Text] [Related]
18. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
19. PAR-2 inhibition reverses experimental pulmonary hypertension.
Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]